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Background: An early sign of heart failure (HF) is a decreased cardiac reserve or inability to adequately increase
cardiac output during exercise. Under normal circumstances maximal cardiac output is closely related to peak
oxygen uptake (VO2peak) which has previously been shown to be closely related to total heart volume (THV). Thus,
the aim of this study was to derive a VO2peak/THV ratio and to test the hypothesis that this ratio can be used to
distinguish patients with HF from healthy volunteers and endurance athletes. Thirty-one patients with HF of
different etiologies were retrospectively included and 131 control subjects (60 healthy volunteers and 71 athletes)
were prospectively enrolled. Peak oxygen uptake was determined by maximal exercise test and THV was
determined by cardiovascular magnetic resonance. The VO2peak/THV ratio was then derived and tested.
Results: Peak oxygen uptake was strongly correlated to THV (r
2 = 0.74, p < 0.001) in the control subjects, but not
for the patients (r
2 = 0.0002, p = 0.95). The VO2peak/THV ratio differed significantly between control subjects and
patients, even in patients with normal ejection fraction and after normalizing for hemoglobin levels (p < 0.001). In
a multivariate analysis the VO2peak/THV ratio was the only independent predictor of presence of HF (p < 0.001).
Conclusions: The VO2peak/THV ratio can be used to distinguish patients with clinically diagnosed HF from healthy
volunteers and athletes, even in patients with preserved systolic left ventricular function and after normalizing for
hemoglobin levels.
Introduction
Heart failure (HF) is a complex syndrome associated
with a variety of etiologies and clinical presentations [1]
which implies a major diagnostic challenge. The accu-
racy of diagnosis by clinical means alone is often inade-
quate [2,3]. According to the definition of HF, patients
should exhibit typical symptoms or signs such as breath-
lessness or fatigue at rest or during exercise, pulmonary
congestion or ankle swelling, and objective evidence of
cardiac dysfunction at rest [1]. However, ACC/AHA
have identified 4 stages (A-D) with emphasis on the
evolution and progression of HF, where stage A defines
patients who are at high risk for developing HF but has
no structural disorder of the heart and no signs or
symptoms of HF [4]. Thus, there is a need for diagnostic
methods that can objectify early signs of decreased car-
diac performance in order to optimize management and
treatment to prevent or delay progression of the disease
and consequently improve patient prognosis.
Cardiac performance can be assessed by maximal exer-
cise testing with measurements of respiratory gas
exchange to determine peak oxygen uptake (VO2peak),
shown to be closely correlated to maximal cardiac output
[5,6]. This method is predominantly used in evaluation of
patients with established HF under consideration for
heart transplantation [7,8]. Experimental animal studies
[9,10] and a recent study in humans [11] have shown
that VO2peak is closely correlated to the total heart
volume (THV). Hence, a physiologically enlarged heart
has a proportionally increased VO2peak. A decreased car-
diac reserve and inability to increase cardiac output to
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be the first sign of HF [12].
Cardiovascular magnetic resonance (CMR) is well sui-
ted for determination of the THV, given the completely
three dimensional nature of the technique. CMR is also
considered the gold standard for determination of car-
diac function and dimensions [13].
Therefore, the aim of this study was to use maximal
exercise testing with measurements of respiratory gas
exchange and CMR to derive a VO2peak/THV-index as
a novel measure of the cardiac reserve and to test if this
can be used to distinguish patients with HF from
healthy volunteers and endurance athletes with physio-
logically enlarged hearts.
Methods
Study population and design
This study follows the Declaration of Helsinki and was
approved by the regional ethics committee. All study
subjects gave their informed consent to participate in
the study.
Thirty-one patients (5 females) who had been clinically
diagnosed with HF with varying etiology were retrospec-
tively enrolled and compared with 60 healthy volunteers
(20 females) from the local community and 71 elite ath-
letes (30 soccer players [12 females], 23 European hand-
ball players [12 females] and 18 triathletes [6 females])
prospectively enrolled in the study. All underwent both
CMR and maximal incremental exercise testing on erg-
ometer cycle, with measurement of respiratory gas
exchange, within a month for the patients and within a
week for the healthy volunteers and athletes. Hemoglobin
level was assessed within 2 weeks of the exercise test in
patients and on the day of the exercise test in healthy
volunteers and athletes who gave their consent for blood
sampling.
CMR and analysis
CMR was performed on a 1.5 T system (Philips Intera
CV; Philips, Best, The Netherlands) with a cardiac
synergy coil. All subjects were placed in supine position.
Cine short-axis gradient-recalled echo images covering
the entire heart from base of the atria to the ventricular
apex were acquired using a steady state free precession
sequence - slice thickness = 8 mm, field-of-view = 340 mm,
repetition time = 3.14 ms, echo time = 1.58 ms.
For viability assessment in the patients, late gadoli-
nium enhancement (LGE) images were acquired 20–30
minutes after intravenous injection of an extracellular
gadolinium-based contrast agent (gadoteric acid,
Gd-DOTA, 0.2 mmol/kg, Guerbet, Gothia Medical AB,
Billdal, Sweden). An inversion-recovery (IR) sequence
was applied in the corresponding short-axis planes as for
the cine images. Typical IR sequence parameters were:
slice thickness = 8 mm, repetition time = 3.9 ms, echo
time = 1.2 ms, in-plane resolution = 1.5 × 1.5 mm and
flip angle = 15° with acquisition every heartbeat. The
inversion time, typically 200–300 ms, was manually
adjusted to null the signal from remote myocardium [14].
Volumetric measurements
Total heart volume was measured in the cine short-axis
images by planimetry as previously described [15]. In
short, THV was defined as the volume of all structures
within the pericardium, including myocardium, blood
pool, atria and pericardial fluid. This also includes the
proximal parts of the great vessels covered by the peri-
cardium. A region of interest was manually drawn
around the pericardial border in all the short-axis
images of the heart in end-diastole (Figure 1) using a
freely available software (Segment 1.697; http://segment.
heiberg.se) [16]. The summed area was then multiplied
with slice thickness to obtain THV. The volumetric
method used to determine THV has previously been
applied in studies of cardiac pumping mechanics
[15,17-21].
Furthermore, endocardial borders of the left ventricular
(LV) myocardium were manually delineated in end-diasto-
lic and end-systolic short-axis images, enabling calculation
of LV end-diastolic and end-systolic volumes (LVEDV and
LVESV) as well as LV ejection fraction (LVEF). In addi-
tion, the epicardial borders of the left ventricle were deli-
neated for determination of LV mass (LVM).
Viability assessment
Myocardial scar/fibrosis was assessed by manual delinea-
tion of the hyperenhanced myocardium in the LGE
short-axis images.
Exercise test with respiratory gas analysis
A maximal incremental exercise test was performed
using an electronically braked cycle ergometer (Siemens
Ergomed 940, Upplands Väsby, Sweden) with respiratory
gas analysis equipment (Oxycon Champion, Jaeger,
Hochberg, Germany). The test protocols were chosen to
yield exercise duration of approximately 8-12 minutes,
yielding starting stress between 10-150 W with 10-30 W
increment per minute. Peak oxygen uptake was defined
as the highest value reached at the end of exercise and
expressed both as ml min




A 12-lead ECG was acquired throughout the test.
Blood pressure was measured by sphygmanometer in
the supine position before exercise, every two minutes
during exercise on the ergometer cycle and in the
supine position at rest after exercise.
VO2peak/THV ratio
A ratio between VO2peak and THV was derived. Further-
more, the ratio was also normalized to hemoglobin levels
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capacity in peripheral tissue in the presence of anemia.
The VO2peak/THV ratio was also compared to levels of
plasma amino terminal pro-brain natriuretic peptide
(pro-BNP) for the patients who had a pro-BNP taken
within 4 months of the exercise test.
Statistical analysis
Values are shown as mean ± standard deviation. Uni-
variate linear regression analysis was used to assess the
correlation between VO2peak and THV as well as body
weight. Unpaired T-test was used to assess differences
between variables where normal distribution was
assumed. The Mann-Whitney test was used to assess
differences where normal distribution could not be
assumed. Forward stepwise multivariate regression ana-
lysis was performed to assess the independent predictive
values of THV, LVEF, LVEDV, VO2peak, VO2peakkg
and the VO2peak/THV ratio for presence of HF. Recei-
ver operating characteristic (ROC) analysis was per-
formed to test the ability of the VO2peak/THV ratio to
distinguish between HF patients and controls. All statis-
tical analysis was performed using SPSS 16.0 (Chicago,
IL, USA). A p-value of <0.05 was considered statistically
significant.
Results
Subject characteristics are seen in Table 1. Twelve patients
had been diagnosed with dilated cardiomyopathy, five
patients with ischemic cardiomyopathy, three patients
with suspected myocardial hemocromatosis, two patients
with hypertrophic cardiomyopathy, two patients with con-
genital heart disease, two patients with constrictive cardio-
myopathy, one patient with post-partum cardiomyopathy,
Figure 1 Delineation of total heart volume. Example of delineation of the pericardium from short-axis cardiac magnetic resonance images
enabling determination of the total heart volume. The base is seen in the upper left corner and apex in the lower right corner. Ao = ascending
aorta, LA = left atrium, LV = left ventricle, Pulm = pulmonary artery, RA = right atrium, RV = right ventricle.
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three patients with HF of unknown cause. In 16% (5/31)
of the patients there were signs of scarred/fibrous myo-
cardium on the LGE images. Hemoglobin levels were
assessed the same day as the exercise test in 65% (39/60)
of the healthy volunteers and in 73% (52/71) of 71
athletes (hemoglobin levels were not assessed in the
triathletes) and within 2 weeks of the exercise test in
97% (30/31) of the patients.
The inter-observer variabililty for measuring THV was
-5±37 ml (r
2 = 0.96, p < 0.001).
Peak oxygen uptake vs cardiac characteristics and body
weight
There was a strong correlation (r
2 = 0.74, p < 0.001)
between VO2peak and THV for the control subjects
(healthy volunteers and athletes) but no correlation (r
2 =
0.0002, p = 0.95) for HF patients (Figure 2A). Figure 2B
shows only a moderate correlation (r
2 = 0.37, p < 0.001)
between VO2peak and body weight in the control sub-
jects with a considerable variation in VO2peak for a given
body weight.
Even though a significant difference in LVEF was
found between the control subjects and the HF patients
(p < 0.001; Figure 3A), there was a significant overlap
with 29% (9/31) of the HF patient examinations showing
LVEF > 50%. Figure 3B shows a comparison between
control subjects and HF patients with LVEF > 50%,
where the HF patients had a slightly higher LVEF (p =
0.04). Despite the higher LVEF in these patients, the
VO2peak/THV ratio was significantly lower compared
to the control subjects (p < 0.001; Figure 3C).
VO2peak/THV ratio
Figure 4A shows the VO2peak/THV ratio for each sub-
ject group. The HF patients showed a significantly lower
VO2peak/THV ratio (p < 0.001) than the other subject
groups, even after normalizing for hemoglobin levels
(p < 0.001, Figure 4B).
When dividing the different subgroups with regard to
VO2peak alone, there was still a significant difference
between healthy volunteers and HF patients (3102 ± 696




Number n = 60 n = 71 n = 31
Gender (M/F) 40/20 41/30 26/5
Age (years) 35 ± 11 26 ± 7*** 54 ± 12***
Weight (kg) 75 ± 11 75 ± 11 80 ± 15
Height (m) 1.77 ± 0.08 1.78 ± 0.08 1.74 ± 0.08
SBP (mmHg) 127 ± 9 126 ± 9 107 ± 12***
DBP (mmHg) 74 ± 8 72 ± 8 69 ± 9**
VO2peak (ml min








41 ± 7 52 ± 7*** 16 ± 5***
LVEDV (ml) 183 ± 31 223 ± 39*** 280 ±
132***
LVM (g) 105 ± 25 130 ± 34*** 177 ± 87***




LVEF (%) 62 ± 6 58 ± 6** 37 ± 22***
DBP = diastolic blood pressure, LVEDV = left ventricular end-diastolic volume,
LVEF = left ventricular ejection fraction, LVM = left ventricular mass, SBP =
systolic blood pressure, THV = total heart volume, VO2peak = peak oxygen
uptake, **p < 0.01, ***p < 0.001 compared to the healthy volunteers.
Figure 2 Peak oxygen uptake in relation to total heart volume and body weight. Peak oxygen uptake (VO2peak) in comparison to A) total
heart volume (THV) and B) body weight. Filled circles denote control subjects, including healthy volunteers and athletes and open circles
denote heart failure patients. Solid lines represent the regression line and dashed lines the 95% confidence interval. In the control group there
was a strong correlation between VO2peak and THV. Even though there was also a significant correlation between VO2peak and body weight,
there was a considerable variation of VO2peak for a given body weight.
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considerable overlap between the two groups (Figure 5A).
Ten control subjects and 10 HF patients had overlapping
VO2peak (Figure 5B). The VO2peak/THV ratio, however,
differed significantly between these two groups (p <
0.001) (Figure 5C). The LVEF for the overlapping healthy
volunteers did not differ significantly from the overlap-
ping HF patients (42 ± 25% vs 61 ± 5%; p = 0.11),
whereas THV was significantly larger for the latter (640
± 66 vs 1092 ± 336 ml/min; p < 0.001).
In 68% (21/31) of the HF patients a pro-BNP was taken
11 ± 25 days from the exercise test. There was a significant
correlation between decreasing VO2peak/THV ratio and
increasing pro-BNP (r
2 = 0.42, p = 0.002).
Furthermore, the VO2peak/THV ratio was the only
independent predictor of HF (p < 0.001; Table 2). The
area under the curve (AUC) for the VO2peak/THV ratio
to diagnose HF was 1.0. With a cut-off value of 3.0, the
VO2peak/THV ratio had a sensitivity of 100% and a spe-
cificity of 97%. Even though there was a slight decrease
in VO2peak/THV ratio with increasing age, there was a
significant difference between patients and healthy
volunteers for all age groups (Figure 6).
Discussion
This study shows that a VO2peak/THV ratio can be
used to distinguish patients with HF from healthy
volunteers and athletes, even in patients with preserved
Figure 4 VO2peak/THV ratio in heart failure patients and control subjects.V O 2peak/THV ratio in heart failure patients compared to healthy
volunteers and different groups of athletes. The VO2peak/THV ratio was significantly lower in the heart failure patients compared to the control
groups (A). This relationship remained unchanged after normalizing the results to hemoglobin levels (B). The solid line represents the mean
value. ** p < 0.01 and *** p < 0.001 compared to healthy volunteers.
Figure 3 Left ventricular ejection fraction in relation to VO2peak/THV ratio. Left ventricular ejection fraction (LVEF) for A) all subjects and
B) control subjects and heart failure patients with LVEF > 50% and C) VO2peak/THV ratio for the control subjects and heart failure patients with
LVEF > 50%. In the heart failure patients with LVEF > 50% there was a significantly lower VO2peak/THV ratio despite a slightly higher LVEF
compared to the control subjects. The solid line represents the mean value. * p < 0.05 and *** p < 0.001
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bin levels.
Clinical use of the proposed VO2peak/THV ratio
It is expected that the VO2peak/THV ratio will drop in
the presence of HF, since cardiac output, and conse-
quently VO2peak, is disproportional to the metabolic
requirements of the peripheral tissue in the situation of
a failing heart. However, when and in which stage of HF
development the VO2peak/THV ratio decreases is not
known. A decreased VO2peak/THV ratio could poten-
tially be seen in patients with no symptoms at rest and
in the absence of significant structural cardiac
abnormalities.
Figure 5 Peak oxygen uptake in comparison to VO2peak/THV ratio.P e a ko x y g e nu p t a k e( V O 2peak) for the healthy volunteers and the HF
patients (A) which showed a considerable overlap (B). The VO2peak/THV ratio was, however, significantly lower in the 10 heart failure patients
compared to the 10 healthy volunteers with overlapping VO2peak (C). Dashed lines indicate the overlap between the two groups and the solid
lines represents mean values. *** p < 0.001
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of respiratory gases and analysis of VO2peak is predomi-
nantly used in patients with terminal HF under consid-
eration for heart transplantation [7]. The present study
suggests that assessment of VO2peak in relation to THV
for determination of a VO2peak/THV ratio can be of
potential use even in non-terminal and early stage HF,
maybe even before the patient exhibit symptoms, such
as in stage A HF [4]. Another possible application of a
VO2peak/THV ratio is in management of patients with
a history of endurance training and a sudden change in
exercise capacity. These patients might perform within
normal limits during a maximal exercise test with analy-
sis of respiratory gases when compared to age and gen-
der matched controls. However, in relation to THV the
working capacity might be decreased which would be
detected by a low VO2peak/THV ratio as an indicator of
early stage HF. This is supported by the findings that
the healthy volunteers and the HF patients with overlap-
ping VO2peak showed a significant difference in
VO2peak/THV ratio with almost no overlap, indicating
that the ratio has additional diagnostic value. Further-
m o r e ,L V E Fw a sn o ts t a t i s t i c ally significant different
between the two overlapping groups. Thus, VO2peak/
THV provides diagnostic information beyond LVEF.
Even though there was a significant difference between
control subjects and HF patients with regard to LVEF in
the present study, almost 30% of the patients had nor-
mal LVEF. However, these patients had significantly
lower VO2peak/THV ratio than the control subjects
with almost no overlap. Thus, VO2peak/THV ratio may
also be used as a marker of HF in patients with pre-
served systolic LV function.
Heart failure is often described based on clinical
symptoms as being mild, moderate, or severe. Mild HF
is used for patients with no significant physical limita-
tions due to dyspnoea or fatigue and severe HF is used
for patients who are markedly symptomatic with a need
for frequent medical attention. Moderate HF is used for
the remaining patients. For clinical management of HF
patients and for randomized clinical trials, the New
York Heart Association (NYHA) functional classification
[22,23] is often employed. However, the accuracy of
diagnosing HF by clinical means alone is often inade-
quate [2,3]. Hence, there is a need for objective mea-
sures of cardiac performance in order to determine the
efficiency of different therapeutic strategies in rando-
mized clinical trials.
The clinical use a VO2peak/THV ratio could poten-
tially complement commonly used cardiac diagnostic
biomarkers such as ECG and biochemical markers. A
commonly used biochemical marker for severity of HF
is pro-BNP, which has been shown to correlate with
the severity of HF [24,25]. In the present study,
the VO2peak/THV ratio was shown to correlate with
pro-BNP, indicating that the ratio can potentially serve
as a measure for severity of HF.
Normalization of peak oxygen uptake to cardiac
dimension rather than body weight
Lower limits for VO2peak are usually determined in
relation to body weight and used to determine if a
patient is suitable for heart transplantation or not
[26,27]. However, the present study show a considerable
variability in VO2peak for a given body weight (Figure 2B).
T o t a lh e a r tv o l u m e ,h o w e v e r ,w a ss h o w nt ob ec l o s e l y
correlated to VO2peak in healthy volunteers and ath-
letes but not in HF patients. Thus, for the non-failing
heart, the VO2peak/THV ratio is preserved in the pre-
sence of a physiologically enlarged heart, whereas for
the failing heart the VO2peak/THV ratio is not pre-
served as THV increases due to pathological enlarge-
m e n to ft h eh e a r t .T h i ss u g g e s t st h a tV O 2peak should
be normalized to THV and not to body weight. This is
Table 2 Forward stepwise multivariate regression
analysis for prediction of heart failure
Beta-value (r-value) p-value
VO2peak/THV ratio -0.90 < 0.0001









LVEDV = left ventricular end-diastolic volume, LVEF = left ventricular ejection
fraction, THV = total heart volume, VO2peak = peak oxygen uptake.
Figure 6 VO2peak/THV ratio in different age groups.V O 2peak/
THV ratio in healthy volunteers and in heart failure patients in
different age groups. Even though there was a slight decrease in
VO2peak/THV ratio with increasing age in the healthy volunteers,
VO2peak/THV ratio remained significantly higher in the healthy
volunteers compared to the heart failure patients. * p < 0.05 and
*** p < 0.001
Engblom et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:74
http://www.jcmr-online.com/content/12/1/74
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experimental animal studies [9,10] showing that
VO2peak is determined primarily by cardiac dimension
and not peripheral factors such as the efficiency of oxy-
gen uptake in peripheral tissue [29]. This is also sup-
p o r t e db yt h ep r e s e n ts t u d ys h o w i n gt h a taV O 2peak/
THV ratio is significantly lower in HF compared to
healthy volunteers and athletes even after normalizing
for hemoglobin levels.
Determination of total heart volume
I nt h ep r e s e n ts t u d yT H Vw a sd e t e r m i n e db yC M R ,
which is considered the gold standard for assessing car-
diac dimensions and function [13]. In situations when
CMR is not available or is contraindicated, i.e. in
patients with biventricular pacing, THV could poten-
tially also be determined by low dose-cardiac CT, pre-
ferably gated. However, non-gated examinations would
also be possible if CT thorax is performed for other rea-
sons, since THV varies little during the cardiac cycle
[15,17,18]. Three dimensional echocardiography might
potentially also be used to determine THV, although
this technique may suffer from incomplete coverage of
the tissue within the pericardium. By using the THV,
enlargement of all cardiac chambers including the atria
is considered. Enlargement of the left atrium has been
shown to provide prognostic value in HF patients with
normal LVEF [30].
Limitations
The results of the present study should be interpreted in
the light of some limitations. The number of patients in
the present study is limited and the patients were retro-
spectively included with clinically diagnosed HF and
clinically determined etiology. Thus, no specific HF
inclusion criteria based on biochemical markers, ECG or
echocardiographic variables were applied. Furthermore,
the patients had different etiologies and different stages
of HF. However, this pilot study can be considered a
proof of the concept study for determining a VO2peak/
THV ratio as an objective measure of cardiac capacity,
independent of HF etiology.
Due to symptoms during the exercise test, HF patients
might not reach VO2peak representative of the indivi-
dual’s actual maximal oxygen uptake capacity. For this
reason VO2peak is referred to as peak and not maximal
oxygen uptake in the present study.
There was a significant difference in mean age
between the patient population and the control groups.
However, the slight decrease in VO2peak/THV ratio
found with increased age in the healthy volunteers (21-
65 years) is negligible compared to the decrease in
VO2peak/THV ratio found in the HF patients.
Since VO2peak can not be obtained in HF patients with
acute decompensation, the VO2peak/THV ratio can not
be used in these patients. The VO2peak/THV ratio
might, however, be of significant benefit when the HF
diagnosis is uncertain, such as in the situation of stage A
HF or if the progression of the disease is less clear.
Furthermore, the prognostic value of the VO2peak/
THV ratio also remains to be determined in prospective
follow-up studies of different patient groups with estab-
lished HF or at risk for developing HF.
Conclusions
The VO2peak/THV ratio can be used to distinguish
patients with known HF from healthy volunteers and
athletes, even in patients with preserved systolic LV
function and after normalizing for hemoglobin levels.
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